A study co-led by WEHI and the Peter Doherty Institute for Infection and Immunity has found that existing HIV drugs can suppress transmission of the HTLV-1 virus in mice.

Dr Oliver Sartor is an internationally recognised medical oncologist and scientist specialising in prostate cancer and radiopharmaceutical therapies.

Viral Vector Manufacturing Facility and Cell Therapies have signed an MoU to explore strategic collaboration opportunities aimed at strengthening the onshore development and manufacture of Advanced Therapy Medicinal Products.

Lumos Diagnostics (ASX:LDX) has signed an exclusive US distribution and supply agreement for FebriDx, valued at up to US$317 million (approximately AUD$487 million), with PHASE Scientific International.

Imugene (ASX:IMU) has announced it has received firm commitments from institutional and sophisticated investors for a $22.5 million placement and is launching a share purchase plan for existing eligible shareholders to raise up to $15 million.

Brandon BioCatalyst has welcomed the inclusion of its national biotechnology incubator, CUREator, in a new $100 million program funded by the Australian Government's Medical Research Future Fund.

Australian clinical-stage biotechnology company Noxopharm (ASX:NOX) has announced the administration of the first SOF-SKN dose in the HERACLES trial.

Health Minister Mark Butler has launched the Cancer Australia Research Initiative, a new program designed to address emerging needs in cancer research.

Health Minister Mark Butler has announced $100 million in funding to three organisations for emerging Australian biomedical and medical technology innovations.

Over 1,000 professionals from across the life sciences sector have already taken part in On Q Recruitment's 2025 Salary and Job Market Survey.

Scientists from the Centenary Institute and the University of Sydney have made a discovery that could lead to safer and more effective gene therapies for a range of serious genetic disorders, including Duchenne muscular dystrophy, Pompe disease and haemophilia.

Amplia Therapeutics (ASX:ATX) has announced that an additional confirmed partial response has been recorded in its ongoing ACCENT clinical trial in pancreatic cancer.

Clinical-stage immunooncology company Imugene (ASX:IMU) has announced new data from its Phase 1b clinical trial evaluating azer-cel (azercabtagene zapreleucel) in patients with relapsed or refractory diffuse large B-cell lymphoma.

Australian antiviral drug development company, Island Pharmaceuticals (ASX:ILA), has signed an agreement to acquire the galidesivir antiviral program from US-based BioCryst Pharmaceuticals.

Neurizon Therapeutics (ASX:NUZ) reports progress across key clinical and regulatory activities for its lead program, NUZ-001, targeting the treatment of amyotrophic lateral sclerosis.

Race Oncology (ASX:RAC) has secured Human Research Ethics Committee approvals from the Institutional Review Board of The University of Hong Kong to commence its Phase 1 clinical trial of RC220 in combination with doxorubicin at the Prince of Wales and Queen Mary Hospitals.

Imagion Biosystems (ASX:IBX) has updated investors on its planned Phase 2 HER2 breast cancer clinical trial to be conducted in the US.